AirSculpt Technologies, Inc. (AIRS)
| Market Cap | 38.49M -93.6% |
| Revenue (ttm) | 147.68M -6.3% |
| Net Income | -9.40M |
| EPS | -0.14 |
| Shares Out | 72.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,172,751 |
| Open | 0.9893 |
| Previous Close | 1.4400 |
| Day's Range | 0.5155 - 1.0150 |
| 52-Week Range | 0.5155 - 10.6300 |
| Beta | 2.28 |
| Analysts | Buy |
| Price Target | 4.00 (+649.2%) |
| Earnings Date | Nov 6, 2026 |
About AIRS
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an adv... [Read more]
Financial Performance
In 2025, AirSculpt Technologies's revenue was $151.82 million, a decrease of -15.82% compared to the previous year's $180.35 million. Losses were -$11.67 million, 45.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for AIRS stock is "Buy." The 12-month stock price target is $4.0, which is an increase of 649.20% from the latest price.
News
AirSculpt Technologies Earnings Call Transcript: Q3 2026
Q3 revenue and adjusted EBITDA declined amid weaker lead generation from Google AI Overviews and execution issues at several centers. FY26 guidance was lowered; refinancing extends debt maturity to 2031, while GLP-1 procedures reached nearly 10% of cases.
AirSculpt Technologies Earnings release: Q3 2026
AirSculpt Technologies released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
AirSculpt Technologies Quarterly report: Q3 2026
AirSculpt Technologies has published its Q3 2026 quarterly earnings report on November 6, 2026.
AirSculpt Technologies reports Q3 adjusted EPS (8c), consensus (3c)
Reports Q3 revenue $31.94M, consensus $34.51M. Yogi Jashnani, Chief Executive Officer, stated: “While our third quarter results were below expectations, we identified the key drivers and are addressin...
AirSculpt Technologies cuts FY26 revenue view to $144M-$146M from $151M-$157M
FY26 consensus $151.05M. Cuts FY26 adjusted EBITDA view to $9M-$10M from $12M-$14M.
AirSculpt Technologies Reports Third Quarter Fiscal 2026 Results
TAMPA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced resu...
AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Third Quarter Fiscal 2026 Results
MIAMI BEACH, Fla., Nov. 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, t...
AirSculpt Technologies initiated with a Buy at Lake Street
Lake Street analyst Ben Haynor initiated coverage of AirSculpt Technologies (AIRS) with a Buy rating and $3 price target AirSculpt’s core fat removal procedures were waylaid by GLP-1s, with same-cente...
AirSculpt Technologies initiated with a Buy at Titan Partners
Titan Partners initiated coverage of AirSculpt Technologies (AIRS) with a Buy rating and $5 price target The firm views the company as a premium provider of minimally invasive body-contouring procedur...
AIRS Investors Have Opportunity to Join AirSculpt Technologies, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $AIRS--AIRS Investors Have Opportunity to Join AirSculpt Technologies, Inc. Fraud Investigation with SBS Law.
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
AirSculpt Technologies Slides: Investor presentation
AirSculpt Technologies has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
AirSculpt Technologies management to meet virtually with Maxim
Virtual Meeting to be held on August 19 at 11 am hosted by Maxim.
AirSculpt Technologies Transcript: Canaccord Genuity's 46th Annual Growth Conference
The business has stabilized with positive case growth, driven by new talent and improved sales and marketing. Significant growth is expected from GLP-1 related procedures and new offerings like alloClae, with plans to expand locations once further stabilization and debt refinancing are achieved.
AirSculpt Technologies Earnings Call Transcript: Q2 2026
Stable revenue and positive case growth were achieved, driven by expanded procedures and targeted marketing to GLP-1 patients. Guidance was reaffirmed at the lower end, with increased marketing spend expected to support future growth. Liquidity and balance sheet strength improved.
AirSculpt Technologies Earnings release: Q2 2026
AirSculpt Technologies released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
AirSculpt Technologies Quarterly report: Q2 2026
AirSculpt Technologies has published its Q2 2026 quarterly earnings report on August 10, 2026.
AirSculpt Technologies reports Q2 EPS (2c) vs. (1c) last year
Reports Q2 revenue $42.9M, consensus $44.14M. CEO Yogi Jashnani stated: “In Q2, we advanced our key priorities – delivering our second quarter of stability. During the quarter, we stepped up…
AirSculpt Technologies still sees 2026 revenue at lower end of $151M-$171M
2026 revenue consensus $153.19M. Reducing 2026 adjusted EBITDA view to $12M-$14M.
AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results
MIAMI BEACH, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announce...
AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal 2026 Results
Company to Participate in Canaccord Genuity's 46th Annual Growth Conference Company to Participate in Canaccord Genuity's 46th Annual Growth Conference
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions
HONG KONG & SEOUL, South Korea--(BUSINESS WIRE)--AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“T...
AirSculpt Technologies Transcript: Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference
A transformation driven by new leadership and enhanced marketing has led to positive same-store sales and renewed growth, with significant opportunities in GLP-1-related procedures and further footprint expansion. Financial flexibility is supported by improved margins and a strengthened balance sheet.
AirSculpt Technologies Transcript: TD Cowen 10th Annual Future of the Consumer Conference
AirSculpt is experiencing renewed growth through enhanced marketing, service expansion targeting GLP-1 medication users, and strong clinic-level economics. With a focus on operational efficiency, geographic expansion, and capturing new market segments, management sees significant long-term revenue potential.
AirSculpt Technologies Announces Participation in Upcoming Investor Conferences
MIAMI BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, t...